schliessen

Filtern

 

Bibliotheken

Hyperfibrinogenemia predicts poor prognosis in patients with advanced biliary tract cancer

Hyperfibrinogenemia reportedly predicts poor prognosis in several cancers but has not been reviewed for biliary tract cancer (BTC). The aim of the present study was to evaluate associations between baseline plasma fibrinogen concentrations, clinicopathological characteristics, and survival parameter... Full description

Journal Title: Tumor biology 2015-10-09, Vol.37 (3), p.3535-3542
Main Author: Li, Heming
Other Authors: Zhao, Tong , Ji, Xuening , Liang, Shanshan , Wang, Zhe , Yang, Yulong , Yin, Jiajun , Wang, Ruoyu
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: Dordrecht: Springer Netherlands
ID: ISSN: 1010-4283
Link: https://www.ncbi.nlm.nih.gov/pubmed/26453118
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_1784749434
title: Hyperfibrinogenemia predicts poor prognosis in patients with advanced biliary tract cancer
format: Article
creator:
  • Li, Heming
  • Zhao, Tong
  • Ji, Xuening
  • Liang, Shanshan
  • Wang, Zhe
  • Yang, Yulong
  • Yin, Jiajun
  • Wang, Ruoyu
subjects:
  • Aged
  • Analysis
  • Biliary Tract Neoplasms - blood
  • Biliary Tract Neoplasms - mortality
  • Biliary Tract Neoplasms - pathology
  • Biomedical and Life Sciences
  • Biomedicine
  • Cancer
  • Cancer patients
  • Cancer Research
  • Disease-Free Survival
  • Female
  • Fibrin
  • Fibrinogen
  • Fibrinogen - analysis
  • Humans
  • Male
  • Medical prognosis
  • Medical research
  • Medicine, Experimental
  • Middle Aged
  • Neoplasm Staging
  • Original Article
  • Prognosis
  • Retrospective Studies
  • Studies
ispartof: Tumor biology, 2015-10-09, Vol.37 (3), p.3535-3542
description: Hyperfibrinogenemia reportedly predicts poor prognosis in several cancers but has not been reviewed for biliary tract cancer (BTC). The aim of the present study was to evaluate associations between baseline plasma fibrinogen concentrations, clinicopathological characteristics, and survival parameters in patients with BTC. Data for 127 patients with BTC diagnosed at the Zhongshan Affiliated Hospital of Dalian University (Liaoning, China) from January 2011 to December 2014 were retrospectively evaluated. Associations between baseline fibrinogen concentrations, selected clinicopathological characteristics, and the prognostic value were examined using SPSS software. Data for 37 patients (29.1 % of study cohort) who had undergone curative intent surgery and 90 (70.9 %) with advanced biliary tract cancer (ABTC) were analyzed. The mean plasma fibrinogen concentration 4.0 ± 0.9 g/L for the entire cohort. The percentages with hyperfibrinogenemia (>4 g/L) were 45.7, 37.8, and 48.9 % overall and in the surgical and ABTC groups, respectively. Hyperfibrinogenemia was associated with performance status (PS) and neutrophil/lymphocyte ratio in the entire cohort but not with other relevant clinicopathological factors. Log-rank test indicated that baseline hyperfibrinogenemia was associated with decreased progression-free survival (PFS) and overall survival (OS) for patients with unresectable ABTC ( P  > 0.05). Multivariate analysis showed that poor PS and baseline hyperfibrinogenemia were independently associated with worse survival (HR: 1.39, 95 % CI: 1.02–1.90, P  = 0.04; HR: 1.75.95 %, 95 % CI: 1.01–3.01, P  = 0.04, respectively). Baseline hyperfibrinogenemia is an independent predictor of poor prognosis in patients with ABTC. Baseline plasma fibrinogen concentrations may be a readily available and inexpensive prognostic biomarker in patients with ABTC; this needs further validation in large prospective clinical trials.
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 1010-4283
fulltext: fulltext
issn:
  • 1010-4283
  • 1423-0380
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.4091501
LOCALfalse
PrimoNMBib
record
control
sourceidgale_proqu
recordidTN_cdi_proquest_miscellaneous_1784749434
sourceformatXML
sourcesystemPC
galeidA450606329
sourcerecordidA450606329
originalsourceidFETCH-LOGICAL-c402t-cb8afe321d46682036f8f3323a46ebaed09eadf2c0fdd71e098060f490b39593
addsrcrecordideNp9UU1rFTEUDWKxtfoD3MiAm26mzddkMstStBUKbrpyEzLJzTNlXjIm85T-e-8wbZGCkkW-zjmcew4hHxg9Z5T2F5UJ3vctZV0rmZatekVOmOSipULT13imjLaSa3FM3tZ6TxE4DOoNOeZKdoIxfUK-3zzMUEIcS0x5Bwn20TZzAR_dUps554K3vEu5xtrE1Mx2iZDw63dcfjTW_7LJgW_GOEVbHpqlWLc0bn0s78hRsFOF94_7Kbn78vnu6qa9_Xb99erytnWS8qV1o7YBBGdeKqU5FSroIAQXVioYLXg6gPWBOxq87xnQQVNFgxzoKIZuEKfkbJNFnz8PUBezj9XBNNkE-VAN67Xs5SCFROinF9D7fCgJza0oMQgpO46o8w21sxOYmEJep8LlMRyXE4SI75eyQxtK8NUB2wiu5FoLBDOXuMc4DKNmLcpsRRnM36xFGYWcj49WDuMe_DPjqRkE9C9EXVww_JzQTZz-K803ZkXRtIPy15T_JP0B7xmv3A
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid1783934452
display
typearticle
titleHyperfibrinogenemia predicts poor prognosis in patients with advanced biliary tract cancer
sourceAlma/SFX Local Collection
creatorLi, Heming ; Zhao, Tong ; Ji, Xuening ; Liang, Shanshan ; Wang, Zhe ; Yang, Yulong ; Yin, Jiajun ; Wang, Ruoyu
creatorcontribLi, Heming ; Zhao, Tong ; Ji, Xuening ; Liang, Shanshan ; Wang, Zhe ; Yang, Yulong ; Yin, Jiajun ; Wang, Ruoyu
descriptionHyperfibrinogenemia reportedly predicts poor prognosis in several cancers but has not been reviewed for biliary tract cancer (BTC). The aim of the present study was to evaluate associations between baseline plasma fibrinogen concentrations, clinicopathological characteristics, and survival parameters in patients with BTC. Data for 127 patients with BTC diagnosed at the Zhongshan Affiliated Hospital of Dalian University (Liaoning, China) from January 2011 to December 2014 were retrospectively evaluated. Associations between baseline fibrinogen concentrations, selected clinicopathological characteristics, and the prognostic value were examined using SPSS software. Data for 37 patients (29.1 % of study cohort) who had undergone curative intent surgery and 90 (70.9 %) with advanced biliary tract cancer (ABTC) were analyzed. The mean plasma fibrinogen concentration 4.0 ± 0.9 g/L for the entire cohort. The percentages with hyperfibrinogenemia (>4 g/L) were 45.7, 37.8, and 48.9 % overall and in the surgical and ABTC groups, respectively. Hyperfibrinogenemia was associated with performance status (PS) and neutrophil/lymphocyte ratio in the entire cohort but not with other relevant clinicopathological factors. Log-rank test indicated that baseline hyperfibrinogenemia was associated with decreased progression-free survival (PFS) and overall survival (OS) for patients with unresectable ABTC ( P  > 0.05). Multivariate analysis showed that poor PS and baseline hyperfibrinogenemia were independently associated with worse survival (HR: 1.39, 95 % CI: 1.02–1.90, P  = 0.04; HR: 1.75.95 %, 95 % CI: 1.01–3.01, P  = 0.04, respectively). Baseline hyperfibrinogenemia is an independent predictor of poor prognosis in patients with ABTC. Baseline plasma fibrinogen concentrations may be a readily available and inexpensive prognostic biomarker in patients with ABTC; this needs further validation in large prospective clinical trials.
identifier
0ISSN: 1010-4283
1EISSN: 1423-0380
2DOI: 10.1007/s13277-015-4184-6
3PMID: 26453118
languageeng
publisherDordrecht: Springer Netherlands
subjectAged ; Analysis ; Biliary Tract Neoplasms - blood ; Biliary Tract Neoplasms - mortality ; Biliary Tract Neoplasms - pathology ; Biomedical and Life Sciences ; Biomedicine ; Cancer ; Cancer patients ; Cancer Research ; Disease-Free Survival ; Female ; Fibrin ; Fibrinogen ; Fibrinogen - analysis ; Humans ; Male ; Medical prognosis ; Medical research ; Medicine, Experimental ; Middle Aged ; Neoplasm Staging ; Original Article ; Prognosis ; Retrospective Studies ; Studies
ispartofTumor biology, 2015-10-09, Vol.37 (3), p.3535-3542
rights
0International Society of Oncology and BioMarkers (ISOBM) 2015
1COPYRIGHT 2016 Springer
2International Society of Oncology and BioMarkers (ISOBM) 2016
lds50peer_reviewed
citedbyFETCH-LOGICAL-c402t-cb8afe321d46682036f8f3323a46ebaed09eadf2c0fdd71e098060f490b39593
citesFETCH-LOGICAL-c402t-cb8afe321d46682036f8f3323a46ebaed09eadf2c0fdd71e098060f490b39593
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26453118$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Li, Heming
1Zhao, Tong
2Ji, Xuening
3Liang, Shanshan
4Wang, Zhe
5Yang, Yulong
6Yin, Jiajun
7Wang, Ruoyu
title
0Hyperfibrinogenemia predicts poor prognosis in patients with advanced biliary tract cancer
1Tumor biology
addtitle
0Tumor Biol
1Tumour Biol
descriptionHyperfibrinogenemia reportedly predicts poor prognosis in several cancers but has not been reviewed for biliary tract cancer (BTC). The aim of the present study was to evaluate associations between baseline plasma fibrinogen concentrations, clinicopathological characteristics, and survival parameters in patients with BTC. Data for 127 patients with BTC diagnosed at the Zhongshan Affiliated Hospital of Dalian University (Liaoning, China) from January 2011 to December 2014 were retrospectively evaluated. Associations between baseline fibrinogen concentrations, selected clinicopathological characteristics, and the prognostic value were examined using SPSS software. Data for 37 patients (29.1 % of study cohort) who had undergone curative intent surgery and 90 (70.9 %) with advanced biliary tract cancer (ABTC) were analyzed. The mean plasma fibrinogen concentration 4.0 ± 0.9 g/L for the entire cohort. The percentages with hyperfibrinogenemia (>4 g/L) were 45.7, 37.8, and 48.9 % overall and in the surgical and ABTC groups, respectively. Hyperfibrinogenemia was associated with performance status (PS) and neutrophil/lymphocyte ratio in the entire cohort but not with other relevant clinicopathological factors. Log-rank test indicated that baseline hyperfibrinogenemia was associated with decreased progression-free survival (PFS) and overall survival (OS) for patients with unresectable ABTC ( P  > 0.05). Multivariate analysis showed that poor PS and baseline hyperfibrinogenemia were independently associated with worse survival (HR: 1.39, 95 % CI: 1.02–1.90, P  = 0.04; HR: 1.75.95 %, 95 % CI: 1.01–3.01, P  = 0.04, respectively). Baseline hyperfibrinogenemia is an independent predictor of poor prognosis in patients with ABTC. Baseline plasma fibrinogen concentrations may be a readily available and inexpensive prognostic biomarker in patients with ABTC; this needs further validation in large prospective clinical trials.
subject
0Aged
1Analysis
2Biliary Tract Neoplasms - blood
3Biliary Tract Neoplasms - mortality
4Biliary Tract Neoplasms - pathology
5Biomedical and Life Sciences
6Biomedicine
7Cancer
8Cancer patients
9Cancer Research
10Disease-Free Survival
11Female
12Fibrin
13Fibrinogen
14Fibrinogen - analysis
15Humans
16Male
17Medical prognosis
18Medical research
19Medicine, Experimental
20Middle Aged
21Neoplasm Staging
22Original Article
23Prognosis
24Retrospective Studies
25Studies
issn
01010-4283
11423-0380
fulltexttrue
rsrctypearticle
creationdate2015
recordtypearticle
recordideNp9UU1rFTEUDWKxtfoD3MiAm26mzddkMstStBUKbrpyEzLJzTNlXjIm85T-e-8wbZGCkkW-zjmcew4hHxg9Z5T2F5UJ3vctZV0rmZatekVOmOSipULT13imjLaSa3FM3tZ6TxE4DOoNOeZKdoIxfUK-3zzMUEIcS0x5Bwn20TZzAR_dUps554K3vEu5xtrE1Mx2iZDw63dcfjTW_7LJgW_GOEVbHpqlWLc0bn0s78hRsFOF94_7Kbn78vnu6qa9_Xb99erytnWS8qV1o7YBBGdeKqU5FSroIAQXVioYLXg6gPWBOxq87xnQQVNFgxzoKIZuEKfkbJNFnz8PUBezj9XBNNkE-VAN67Xs5SCFROinF9D7fCgJza0oMQgpO46o8w21sxOYmEJep8LlMRyXE4SI75eyQxtK8NUB2wiu5FoLBDOXuMc4DKNmLcpsRRnM36xFGYWcj49WDuMe_DPjqRkE9C9EXVww_JzQTZz-K803ZkXRtIPy15T_JP0B7xmv3A
startdate20151009
enddate20151009
creator
0Li, Heming
1Zhao, Tong
2Ji, Xuening
3Liang, Shanshan
4Wang, Zhe
5Yang, Yulong
6Yin, Jiajun
7Wang, Ruoyu
general
0Springer Netherlands
1Springer
2Springer Nature B.V
scope
0CGR
1CUY
2CVF
3ECM
4EIF
5NPM
6AAYXX
7CITATION
8BSHEE
97T5
107TO
11H94
12K9.
137X8
sort
creationdate20151009
titleHyperfibrinogenemia predicts poor prognosis in patients with advanced biliary tract cancer
authorLi, Heming ; Zhao, Tong ; Ji, Xuening ; Liang, Shanshan ; Wang, Zhe ; Yang, Yulong ; Yin, Jiajun ; Wang, Ruoyu
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-c402t-cb8afe321d46682036f8f3323a46ebaed09eadf2c0fdd71e098060f490b39593
rsrctypearticles
prefilterarticles
languageeng
creationdate2015
topic
0Aged
1Analysis
2Biliary Tract Neoplasms - blood
3Biliary Tract Neoplasms - mortality
4Biliary Tract Neoplasms - pathology
5Biomedical and Life Sciences
6Biomedicine
7Cancer
8Cancer patients
9Cancer Research
10Disease-Free Survival
11Female
12Fibrin
13Fibrinogen
14Fibrinogen - analysis
15Humans
16Male
17Medical prognosis
18Medical research
19Medicine, Experimental
20Middle Aged
21Neoplasm Staging
22Original Article
23Prognosis
24Retrospective Studies
25Studies
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Li, Heming
1Zhao, Tong
2Ji, Xuening
3Liang, Shanshan
4Wang, Zhe
5Yang, Yulong
6Yin, Jiajun
7Wang, Ruoyu
collection
0Medline
1MEDLINE
2MEDLINE (Ovid)
3MEDLINE
4MEDLINE
5PubMed
6CrossRef
7Academic OneFile (A&I only)
8Immunology Abstracts
9Oncogenes and Growth Factors Abstracts
10AIDS and Cancer Research Abstracts
11ProQuest Health & Medical Complete (Alumni)
12MEDLINE - Academic
jtitleTumor biology
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Li, Heming
1Zhao, Tong
2Ji, Xuening
3Liang, Shanshan
4Wang, Zhe
5Yang, Yulong
6Yin, Jiajun
7Wang, Ruoyu
formatjournal
genrearticle
ristypeJOUR
atitleHyperfibrinogenemia predicts poor prognosis in patients with advanced biliary tract cancer
jtitleTumor biology
stitleTumor Biol
addtitleTumour Biol
date2015-10-09
risdate2015
volume37
issue3
spage3535
epage3542
pages3535-3542
issn1010-4283
eissn1423-0380
abstractHyperfibrinogenemia reportedly predicts poor prognosis in several cancers but has not been reviewed for biliary tract cancer (BTC). The aim of the present study was to evaluate associations between baseline plasma fibrinogen concentrations, clinicopathological characteristics, and survival parameters in patients with BTC. Data for 127 patients with BTC diagnosed at the Zhongshan Affiliated Hospital of Dalian University (Liaoning, China) from January 2011 to December 2014 were retrospectively evaluated. Associations between baseline fibrinogen concentrations, selected clinicopathological characteristics, and the prognostic value were examined using SPSS software. Data for 37 patients (29.1 % of study cohort) who had undergone curative intent surgery and 90 (70.9 %) with advanced biliary tract cancer (ABTC) were analyzed. The mean plasma fibrinogen concentration 4.0 ± 0.9 g/L for the entire cohort. The percentages with hyperfibrinogenemia (>4 g/L) were 45.7, 37.8, and 48.9 % overall and in the surgical and ABTC groups, respectively. Hyperfibrinogenemia was associated with performance status (PS) and neutrophil/lymphocyte ratio in the entire cohort but not with other relevant clinicopathological factors. Log-rank test indicated that baseline hyperfibrinogenemia was associated with decreased progression-free survival (PFS) and overall survival (OS) for patients with unresectable ABTC ( P  > 0.05). Multivariate analysis showed that poor PS and baseline hyperfibrinogenemia were independently associated with worse survival (HR: 1.39, 95 % CI: 1.02–1.90, P  = 0.04; HR: 1.75.95 %, 95 % CI: 1.01–3.01, P  = 0.04, respectively). Baseline hyperfibrinogenemia is an independent predictor of poor prognosis in patients with ABTC. Baseline plasma fibrinogen concentrations may be a readily available and inexpensive prognostic biomarker in patients with ABTC; this needs further validation in large prospective clinical trials.
copDordrecht
pubSpringer Netherlands
pmid26453118
doi10.1007/s13277-015-4184-6